Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory phase 2 study of glenzocimab in COVID-19-related acute respiratory distress syndrome
2020-002733-15Phase 2Completed
- Sponsor
- Acticor Biotech
- Start
- Jun 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) and coronavirus pneumonia comparing Glenzocimab + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Progression from moderate to severe respiratory distress at Day 4. Started Jun 2020; status: completed.
02
Drugs
glenzocimab
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-002733-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002733-15.